Compare PROF & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PROF | SERA |
|---|---|---|
| Founded | N/A | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.8M | 75.2M |
| IPO Year | 2017 | 2021 |
| Metric | PROF | SERA |
|---|---|---|
| Price | $5.76 | $1.99 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 116.8K | 22.2K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 25.89 | ★ 32.32 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,098,000.00 | $81,000.00 |
| Revenue This Year | $92.40 | $554.81 |
| Revenue Next Year | $64.10 | $517.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 50.73 | 5.19 |
| 52 Week Low | $3.92 | $1.56 |
| 52 Week High | $8.95 | $3.95 |
| Indicator | PROF | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 25.89 | 45.58 |
| Support Level | $4.97 | $1.88 |
| Resistance Level | $6.06 | $2.07 |
| Average True Range (ATR) | 0.35 | 0.09 |
| MACD | -0.12 | -0.01 |
| Stochastic Oscillator | 9.42 | 12.39 |
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.